Blueprint Medicines Corp
BPMC129.460USD
0.000
Cierre 10/10, 16:00（ET）Cotizaciones retrasadas 15 min
8.36BCap. mercado
PérdidaP/E TTM
Más Datos de Blueprint Medicines Corp Compañía
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Información de Blueprint Medicines Corp
Símbolo de cotizaciónBPMC
Nombre de la empresaBlueprint Medicines Corp
Fecha de salida a bolsaApr 30, 2015
Director ejecutivoMs. Kathryn D (Kate) Haviland
Número de empleados649
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 30
Dirección45 Sidney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02139
Teléfono16173747580
Sitio Webhttps://www.blueprintmedicines.com/
Símbolo de cotizaciónBPMC
Fecha de salida a bolsaApr 30, 2015
Director ejecutivoMs. Kathryn D (Kate) Haviland
Ejecutivos de Blueprint Medicines Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
Por negocioUSD
Nombre
Ganancia
Proporción
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Estadísticas de accionistas
Actualizado: mié., 13 de ago
Actualizado: mié., 13 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Otro
63.83%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Otro
63.83%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
42.13%
Hedge Fund
26.61%
Investment Advisor/Hedge Fund
24.80%
Research Firm
3.16%
Sovereign Wealth Fund
1.66%
Individual Investor
0.93%
Bank and Trust
0.78%
Pension Fund
0.78%
Venture Capital
0.41%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
701
68.81M
106.41%
-3.22M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
--
0%
-223.92K
-100.00%
T. Rowe Price Associates, Inc.
--
0%
-3.95M
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-182.70K
-100.00%
State Street Global Advisors (US)
--
0%
-453.14K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+18.37K
-100.00%
Macquarie Investment Management
--
0%
-364.73K
-100.00%
AllianceBernstein L.P.
--
0%
-430.85K
-100.00%
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
ProShares Merger ETF
3.21%
AltShares Event-Driven ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.92%
Goldman Sachs Future Health Care Equity ETF
0.84%
Hypatia Women CEO ETF
0.73%
First Trust Mid Cap Growth AlphaDEX Fund
0.58%
iShares Russell 2000 Growth ETF
0.54%
WisdomTree BioRevolution Fund
0.49%
SoFi Next 500 ETF
0.45%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
Ver más
ProShares Merger ETF
Proporción3.21%
AltShares Event-Driven ETF
Proporción1.43%
ProShares Ultra Nasdaq Biotechnology
Proporción0.92%
Goldman Sachs Future Health Care Equity ETF
Proporción0.84%
Hypatia Women CEO ETF
Proporción0.73%
First Trust Mid Cap Growth AlphaDEX Fund
Proporción0.58%
iShares Russell 2000 Growth ETF
Proporción0.54%
WisdomTree BioRevolution Fund
Proporción0.49%
SoFi Next 500 ETF
Proporción0.45%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.43%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
